NEW YORK, August 29, 2025 — Leads & Copy — Mesoblast Limited (ASX:MSB; Nasdaq:MESO) announced its financial results and an operational update for the period ending June 30, 2025. Revenue from cell therapy products increased by 191% to US$17.2 million. The increase was driven by the successful launch of Ryoncil® in the final quarter, with US$13.2 million in gross sales and US$11.3 million in reported net sales after adjustments. Net operating cash spend was US$50.0 million, a 3% increase, inclusive of costs related to commercial team build and product launch. Cash on hand was US$162 million as of June 30, 2025.
Mesoblast was added to the S&P/ASX 200 Index and the Nasdaq Biotechnology Index. The Board of Directors also added Dr. Gregory George MD PhD and Ms. Lyn Cobley. Ryoncil® is the only FDA-approved MSC therapy, used for pediatric SR-aGvHD. Revascor® is being considered for FDA accelerated approval in end-stage HFrEF, and Rexlemestrocel-L is in Phase 3 trial for potential approval in CLBP.
Mesoblast Chief Executive Dr. Silviu Itescu stated that this year was significant for the company with Ryoncil® receiving FDA approval, marking it the first and only FDA-approved mesenchymal stromal cell (MSC) product in the United States. Ryoncil® has been launched for treating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in pediatric patients aged 2 months and older.
Contact:
Paul Hughes
T: +61 3 9639 6036
Contact:
Emma Neal, Allison Worldwide
T: +1 603 545 4843
E: emma.neal@allisonworldwide.com
Contact:
Steve Dabkowski, BlueDot Media
T: +61 419 880 486
E: steve@bluedot.net.au
Source: Mesoblast Limited
